• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Praxis Precision Medicines Inc. (Amendment)

    2/14/24 3:05:31 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRAX alert in real time by email
    SC 13G/A 1 schedule13ga.htm AMENDMENT NO. 1
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
         
         
         
     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 1)*
     
         
     
    Praxis Precision Medicines, Inc.
     
     
    (Name of Issuer)
     
         
     
    Common Stock
     
     
    (Title of Class of Securities)
     

     
    74006W207
     
     
    (CUSIP Number)
     

     
    December 31, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [ ]
    Rule 13d-1(b)
     
    [x]
    Rule 13d-1(c)
     
    [ ]
    Rule 13d-1(d)
     









    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

    1
    Names of Reporting Persons.
     
    Cormorant Global Healthcare Master Fund, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Cayman Islands
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    633,345 shares

    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    633,345 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    633,345 shares
     
    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    7.39%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)


    1
    Names of Reporting Persons.
     
    Cormorant Global Healthcare GP, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    633,345 shares

    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    633,345 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    633,345 shares
     
    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    7.39%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)


    1
    Names of Reporting Persons.
     
    Cormorant Asset Management, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    633,345 shares

    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    633,345 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    633,345 shares
     
    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    7.39%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)


    1
    Names of Reporting Persons.
     
    Bihua Chen
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    633,345 shares

    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    633,345 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    633,345 shares
     
    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    7.39%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    IN (Individual)


    Item 1.
     
     
    (a)
    Name of Issuer
         
       
    Praxis Precision Medicines, Inc.
     
     
    (b)
    Address of Issuer’s Principal Executive Offices
       
     
    99 High Street, 30th Floor, Boston, MA 02110

    Item 2.
     
     
    (a)
    Name of Person Filing
       
     
    Cormorant Global Healthcare Master Fund, LP
    Cormorant Global Healthcare GP, LLC
    Cormorant Asset Management, LP
    Bihua Chen
     
     
    (b)
    Address of Principal Business Office or, if none, Residence
       
     
    200 Clarendon Street, 52nd Floor
    Boston, MA 02116
     
     
    (c)
    Citizenship
       
     
    Cormorant Global Healthcare Master Fund, LP - Cayman Islands
    Cormorant Global Healthcare GP, LLC - Delaware
    Cormorant Asset Management, LP - Delaware
    Bihua Chen - United States
     
     
    (d)
    Title of Class of Securities
       
    Common Stock
     
     
    (e)
    CUSIP Number
         
       
    74006W207


    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
     
    (a)
    [ ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
     
    (b)
    [ ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
     
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
     
    (d)
    [ ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e)
    [ ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
    (g)
    [ ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
     
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j)
    [ ]
    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
     
    (k)
    [ ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership***
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
     
    (a)
    Amount Beneficially Owned***
           
       
    The information set forth in Row 9 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.
           
     
    (b)
    Percent of Class***
           
       
    The information set forth in Row 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.
           
     
    (c)
    Number of shares as to which such person has: ***
           
       
    (i)
    sole power to vote or to direct the vote
           
       
    (ii)
    shared power to vote or to direct the vote
           
       
    (iii)
    sole power to dispose or to direct the disposition of
           
       
    (iv)
    shared power to dispose or to direct the disposition of


    The information set forth in Rows 5 through 8 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.

     
    *** Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”), as reported herein. Cormorant Global Healthcare GP, LLC serves as the general partner of the Master Fund. Cormorant Asset Management, LP serves as the investment manager to the Master Fund. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC and the general partner of Cormorant Asset Management, LP. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein.
     
    The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon (i) a statement in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on November 7, 2023, that there were 128,550,152 shares of Common Stock outstanding as of November 3, 2023, and (ii) a statement in the Issuer's Current Report on Form 8-K, as filed with the Securities and Exchange Commission on December 1, 2023, that the Issuer effected a 1-for-15 reverse stock split on November 28, 2023.

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group

    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group

    Not applicable.
     
    Item 10.
    Certification
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or


    influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
    Exhibits
    Exhibit
     
    99.1
    Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on July 3, 2023.
     
     

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
     
    February 14, 2024
     

     
    CORMORANT GLOBAL HEALTHCARE MASTER
     
    FUND, LP
     
    By:  
    Cormorant Global Healthcare GP, LLC
     
     
    its General Partner
     
     
     
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
     
     
     
     
    CORMORANT GLOBAL HEALTHCARE GP, LLC
     
     
     
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
     
     
     
     
    CORMORANT ASSET MANAGEMENT, LP
     
    By:
    Cormorant Asset Management GP, LLC
     
     
    its General Partner
     
     
     
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
     
     
     
     
    /s/ Bihua Chen
     
    Bihua Chen



    Get the next $PRAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRAX

    DatePrice TargetRatingAnalyst
    2/2/2026$282.00Equal Weight
    Wells Fargo
    12/15/2025$250.00 → $750.00Outperform
    Oppenheimer
    11/19/2025$424.00Buy
    BTIG Research
    6/2/2025$97.00Outperform
    Oppenheimer
    5/7/2025$80.00Buy
    Chardan Capital Markets
    3/3/2025$120.00 → $105.00Buy
    H.C. Wainwright
    2/11/2025$111.00Buy
    Deutsche Bank
    8/5/2024$134.00Outperform
    Oppenheimer
    More analyst ratings

    $PRAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arbuckle Stuart A was granted 1,166 shares (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    2/10/26 4:59:33 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kindler Jeffrey B was granted 1,166 shares (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    2/10/26 4:57:40 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Accounting Officer Mastrocola Lauren covered exercise/tax liability with 344 shares, decreasing direct ownership by 2% to 13,446 units (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    1/13/26 8:20:33 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on February 2, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,964 shares of its common stock to eight new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). T

    2/4/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.

    SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    2/12/26 9:15:03 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Praxis Precision Medicines Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - Praxis Precision Medicines, Inc. (0001689548) (Filer)

    2/10/26 4:52:49 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Praxis Precision Medicines Inc.

    SCHEDULE 13G - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    2/5/26 1:36:41 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Desimone Jill bought $25,375 worth of shares (14,500 units at $1.75) (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    10/10/23 7:41:39 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Praxis Precision Medicines with a new price target

    Wells Fargo initiated coverage of Praxis Precision Medicines with a rating of Equal Weight and set a new price target of $282.00

    2/2/26 6:51:57 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer reiterated coverage on Praxis Precision Medicines with a new price target

    Oppenheimer reiterated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $750.00 from $250.00 previously

    12/15/25 11:26:49 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Praxis Precision Medicines with a new price target

    BTIG Research initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $424.00

    11/19/25 8:58:01 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Financials

    Live finance-specific insights

    View All

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days Initiated two registrational studies for Developmental and Epileptic Encephalopathies (DEEs) programs: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen Relutrigine granted U.S. FDA Breakthrough Therapy Designation for the treatment of seizures associated with SCN2A and SCN8A DEEs, enabling expedited development Cash and investments of approximately $447 million as of June 30, 2025 maintains runway into 2028 Praxi

    8/4/25 8:30:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine

    Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on treatment Rapid and sustained response, with over 54% of patients achieving 50% response in the first week Vormatrigine was generally well tolerated and continues to demonstrate favorable safety profile BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitati

    8/4/25 8:00:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 7:53:30 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:50:15 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:46:12 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Leadership Updates

    Live Leadership Updates

    View All

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. "These leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage developm

    1/8/26 4:45:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

    PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022

    8/8/22 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care